Sulfo-Cubipol Biotin

Order number: 19742

€2,003.00*

Ready to ship today
Quantity

Description

Welcome the new addition to our NativeMP™ Platform: The Cubipol Series.
The proprietary Cubipol backbone, developed in-house, condenses the positive effects of previously available backbones like SMA, DIBMA, and UltrasoluteTM Amphipol. This new development delivers a new multimodal copolymer backbone, making the Cubipol series the first commercially available next-generation copolymer with 4 available off-the-shelf modified variants.
It joins the Next Generation Copolymers AASTY and Ultrasolute™ Amphipol, making solubilization and stabilization of membrane proteins a simpler and more effective endeavor than ever before.

Sulfo-Cubipol Biotin


The low charged, zwitterionic copolymer variation resembles softer surfactants with a high resistance to extreme pH values, ionic strength and divalent ion concentrations (details in the table below). It belongs to the Cubipol class with low charge, which allows for the uninterrupted study of charge-sensitive interactions between membrane proteins and lipids.

This functionalized copolymer is particularly suited for downstream applications that require copolymer stabilization without affecting the protein. These include drug screening, high-throughput processes and assay development.

More applications for biotin-tagged copolymers:
  • Immobilization via SPR, ELISA, etc.
  • Sorting (FACS)
  • Quantification
  • Identification
  • Localization (Electron Microscopy)

Find more of our biotinylated copolymers included in the  NativeMP™ Biotin Kit

If you’re interested in having this functionalization applied to a different copolymer backbone, get in touch with us and we’ll get that project running for you: Contact us
Feature
State Lyophilized Powder, to be solved with water
Full Name Sulfo-Cubipol Biotin in 50 mM HEPES, pH 7.5
Buffer HEPES
pH after solving 7.5
pH Stability of Copolymer 5.0-10
Absorbance at 280nm No
Molecular Weight 14 kDA
Ca2+ tolerance 40 mM
Mg2+ tolerance 40 mM
Solubility > 10% (H2O)
Polymerization Type Free-radical
Shipping Temperature Ambient Temparature
Storage of lyophilized copolymer -20°C for several years
Storage of dissolved copolymer 2-8°C for several days

Lab Results

Hydrpnamic Diameter of Cubipol Nanodiscs
Fig. 1: Hydrodynamic size of Cubipol-DMPC nanodiscs formed with different copolymers. Nanodisc size was measured in 150 mM NaCl, 20 mM HEPES at pH 7.5 and a Copolymer/DMPC weigth ratio of 3/1.
Cubipol Zeta-Potential
Fig. 3: ζ-potential of DMPC nanodiscs formed with different Cubipol copolymers. All four reveal negative net charge. With Glyco-Cubipol being the closest to neutrality at around -15 mV. Meanwhile unmodified Cubipol has the most negative net charge at -25 mV.
SPR Analysis - P2X4 in Biotinylated Copolymer
Fig. 3 A: P2X4, stabilized in a biotinylated copolymer, was used to investigate its binding interaction with the ligand 5-BDBD using Surface Plasmon Resonance (SPR). The membrane protein was immobilized on a Streptavidin chip. After establishing a baseline, the signal increased during the association phase, indicating successful binding of the biotin on the copolymer binding to the streptavidin on the chip. In the dissociation phase, the unbound protein was removed, leaving no free biotinylted copolymer-protein nanodisc in the solution, resulting in a decrease in signal.
SPR Analysis - P2X4 in Biotinylated Copolymer
Fig. 3 B: Following the immobilization of P2X4 on the chip, the analyte 5-BDBD at two concentrations (1 µM and 10 µM) was used to determine the dissociation constant (Kd). The increase in signal during the association phase indicates sucessful binding between the analyte and P2X4, while the decrease in signal in the dissociation phase reflects complex retention. The resulting curves where fitted, and Kd value of 1.6 µM was estimated.

Disclaimer

Patent Pending
The product described above has been developed and produced by Cube Biotech GmbH. Our products are intended for molecular applications. These products are not intended for diagnosis, prevention or treatment of a disease.